Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals

TY - JOUR

T1 - Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals

AU - Patel, Ravi B.

AU - Vaduganathan, Muthiah

AU - Bhatt, Deepak L.

AU - Bonow, Robert O.

N1 - Funding Information: Funding/Support: This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (grant K01HL141589; Dr Mueller), the Alfred P. Sloan Foundation (Dr Dominguez-Bello), the C & D Fund (Dr Dominguez-Bello), and the Emch Fund for Microbial Diversity (Dr Dominguez-Bello). Funding Information: Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering committees); serving as the Deputy Editor of Clinical Cardiology; serving as chair of NCDR-ACTION Registry Steering Committee; serving as chair of VA CART Research and Publications Committee; receiving research funding from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company; receiving royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); serving as site coinvestigator for Biotronik, Boston Scientific, St Jude Medical (now Abbott), and Svelte; serving as trustee for the American College of Cardiology; and performing unfunded research for FlowCo, Merck, Novo Nordisk, PLx Pharma, and Takeda. No other disclosures were reported. Funding Information: Author Affiliations: Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Patel, Bonow); Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts (Vaduganathan, Bhatt); Editor, JAMA Cardiology (Bonow). Corresponding Author: Ravi B. Patel, MD, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair St, Ste 600, Chicago, IL 60611 (ravi.patel@northwestern.edu). Published Online: November 21, 2018. doi:10.1001/jamacardio.2018.3823 Author Contributions: Drs Patel and Vaduganathan had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Patel, Vaduganathan. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Patel, Vaduganathan. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Patel, Vaduganathan. Study supervision: Patel. Conflict of Interest Disclosures: Dr Patel reported being supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant (T32HL069771). Dr Vaduganathan reported being supported by the KL2/ Catalyst Medical Research Investigator Training award (an appointed KL2 award) from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award KL2 TR002542), and serving on advisory boards for Bayer AG and Baxter Healthcare. Dr Bhatt reported serving on advisory boards for Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; serving on the board of directors for the Boston Veterans Affairs Research Institute, Society of Cardiovascular Patient Care, and TobeSoft; serving as chair of the American Heart Association Quality Oversight Committee; serving on the data monitoring committees for Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), and Population Health Research Institute; receiving honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC

PY - 2018/12

Y1 - 2018/12

UR - http://www.scopus.com/inward/record.url?scp=85057125468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057125468&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2018.3823

DO - 10.1001/jamacardio.2018.3823

M3 - Letter

C2 - 30476952

AN - SCOPUS:85057125468

VL - 3

SP - 1249

EP - 1251

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 12

ER -